Could removing lead protect kidneys in diabetes?
NCT ID NCT07709871
First seen Jul 17, 2026 · Last updated Jul 17, 2026
Summary
This study tests whether an oral medication that removes lead from the body can slow kidney function decline in people with type 2 diabetes and high lead levels. Participants take dimercaptosuccinic acid (DMSA) capsules for up to 3 months, then are followed for 12 months. The goal is to see if lowering lead burden helps preserve kidney health.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- oral dimercaptosuccinic acid (DMSA) capsules for lead removal
- What this could lead to
- If it works, this could point toward a way to slow kidney damage in people with type 2 diabetes who have elevated lead levels.
- What could go wrong
- This is a small, single-arm study with no placebo group, so results may be uncertain. The treatment may not meaningfully slow kidney decline or could cause side effects.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for TYPE 2 DIABETIC NEPHROPATHY WITH ELEVATED BLOOD LEAD BURDEN are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••